{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:24:36Z","timestamp":1790501076277,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immunocompromised patients are at increased risk of severe COVID-19 and impaired vaccine response. In this observational prospective study, we evaluated immunogenicity of the BNT162b2 mRNA vaccine in cohorts of primary or secondary immunocompromised patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Five clinical groups of immunocompromised patients [primary immunodeficiency (PID) (n=57), people living with HIV (PLWH) (n=27), secondary immunocompromised patients with a broad variety of underlying rheumatologic (n=23) and homogeneous (multiple sclerosis) neurologic (n=53) conditions and chronic kidney disease (CKD) (n=39)] as well as a healthy control group (n=54) were included. Systemic humoral and cellular immune responses were evaluated by determination of anti-SARS-CoV-2 Spike antibodies using a TrimericS IgG assay (Diasorin) and through quantification of interferon gamma release in response to SARS-CoV-2 antigen with QuantiFERON SARS-CoV-2 assay (Qiagen), respectively. Responses were measured at pre-defined time-points after complete vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All healthy controls, PLWH and CKD-patients had detectable antibodies 10 to 14 days (T2) and 3 months (T3) after administration of the second vaccination. In contrast, only 94.5% of the PID, 50.0% of the rheumatologic and 48.0% of neurologic patients developed antibodies at T2 and only 89.1% of the PID, 52.4% of the rheumatologic and 50.0% of neurologic patients developed antibodies at T3. At T3 no significant differences in cellular response between the healthy control group and the PLWH and CKD groups were found, while proportions of reactive subjects were lower in PID and rheumatologic patients and higher in neurologic patients. Humoral and cellular immune responses significantly correlated in the healthy control, PID, PLWH groups for all 3 antigens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with acquired or inherited immune disorders may show variable immune responses to vaccination with the BNT162b2 mRNA vaccine against SARS-CoV-2. Whether humoral, cellular or both immune responses are delayed depends on the patient group, therapy and individual risk factors. These data may guide the counselling of patients with immune disorders regarding vaccination of SARS-CoV-2.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.858399","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T09:03:54Z","timestamp":1648544634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":56,"title":["Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Matthijs","family":"Oyaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Ang\u00e9lique","family":"De Scheerder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Van Herrewege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laureys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Van Assche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Cambron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Naesens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levi","family":"Hoste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlien","family":"Claes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomeen","family":"Haerynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Kerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Van Laecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Van Biesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Verhasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizaveta","family":"Padalko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2021.104765","article-title":"Longitudinal Follow-Up of IgG Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infected Patients Up to Eight Months After Infection","volume":"136","author":"Van Elslande","year":"2021","journal-title":"J Clin Virol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(21)00460-6","article-title":"Risk Factors and Disease Profile of Post-Vaccination SARS-CoV-2 Infection in UK Users of the COVID Symptom Study App: A Prospective, Community-Based, Nested, Case-Control Study","volume":"22","author":"Antonelli","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa863","article-title":"COVID-19 in Immunocompromised Hosts: What We Know So Far","volume":"72","author":"Fung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.017","article-title":"Impacts of Immunosuppression and Immunodeficiency on COVID-19: A Systematic Review and Meta-Analysis","volume":"81","author":"Gao","year":"2020","journal-title":"J Infect"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.646677","article-title":"Correlation of Vaccine Responses","volume":"12","author":"Zimmermann","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00388-21","article-title":"Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays Among Infected, Recovered, and Vaccinated Groups","volume":"59","author":"Narasimhan","year":"2021","journal-title":"J Clin Microbiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.025","article-title":"Kinetics of SARS-CoV-2 Anti-S IgG After BNT162b2 Vaccination","volume":"39","author":"Grupel","year":"2021","journal-title":"Vaccine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.23.21252230","article-title":"Prior COVID-19 Infection and Antibody Response to Single Versus Double Dose mRNA SARS-CoV-2 Vaccination","author":"Ebinger","year":"2021","journal-title":"medRxiv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.04.017","article-title":"Postvaccine Anti-SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients","volume":"6","author":"Husein","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103524","article-title":"Cellular and Humoral Immunogenicity of a SARS-CoV-2 mRNA Vaccine in Patients on Haemodialysis","volume":"70","author":"Strengert","year":"2021","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16541","article-title":"Prevalence and Predictors of SARS-CoV-2 Antibodies Among Solid Organ Transplant Recipients With Confirmed Infection","volume":"21","author":"Burack","year":"2021","journal-title":"Am J Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.05.004","article-title":"Immunogenicity of GNT162b2 mRNA COVID-19 Vaccine and SARS-CoV-2 Infection in Lung Transplant Recipients","volume":"40","author":"Havlin","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002945","article-title":"Safety and Antibody Response to the First Dose of SARS-CoV2 Messenger RNA Vaccine in Persons With HIV","volume":"35","author":"Rudy","year":"2021","journal-title":"AIDS"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and Immunogenicity of the ChAdOx1nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection: A Single Arm Substudy of a Phase 2\/3 Clinical Trial","volume":"8","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab648","article-title":"The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Responses in People Living With Human Immunodeficiency Virus (HIV)","author":"Woldemeskel","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577746","article-title":"Humoral Immune Response in Multiple Sclerosis Patients Following PfizerBNT162b2 COVID19 Vaccination: Up to 6 Months Cross-Sectional Study","volume":"361","author":"Achiron","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA Vaccination in MS Patients Treated With Disease Modifying Therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00328-3","article-title":"Efficacy and Tolerability of a Third Dose of an mRNA Anti-SARS-CoV-2 Vaccine in Patients With Rheumatoid Arthritis With Absent or Minimal Serological Response Two Previous Doses","volume":"4","author":"Schmiedeberg","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab954","article-title":"Robust T Cell Responses in Anti-CD20 Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study","author":"Madelon","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and Cellular Immunogenicity to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Longitudinal Cohort Study","volume":"4","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenitcity of Pfizer-BioNTech VODI-19 Vaccine in Patients With Inborn Errors of Immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.11.022","article-title":"Immunogenicity and Tolerability of COVID-19 Messenger RNA Vaccines in Primary Immunodeficiency Patients With Functional B-Cell Defects","volume":"149","author":"Pham","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108095","article-title":"The WHO International Standard for COVID-19 Serological Tests: Towards Harmonization of Anti-Spike Assays","volume":"100","author":"Infantino","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021070908","article-title":"Predictors and Dynamics of the Humoral and Cellular Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicentre Observational Study","volume":"32","author":"Van Praet","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2021-0023","article-title":"Evaluation of the Automated LIAISON SARS-CoV-2 TrimericS IgG Assay for the Detection of Circulating Antibodies","volume":"59","author":"Bonelli","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2181","article-title":"Diagnostic Accuracy of Serological Tests and Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody: A Systematic Review and Meta-Analysis","volume":"31","author":"Mekonnen","year":"2020","journal-title":"Rev Med Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01828-20","article-title":"Changes in SARS-CoV-2 Spike Versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population Based Seroprevalence Studies","volume":"95","author":"Fenwick","year":"2020","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa336","article-title":"Correlation Between Commercial Anti-SARS-CoV-2 IgG and Neutralization Assays","volume":"67","author":"Bal","year":"2021","journal-title":"Clin Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh1282","article-title":"Prior SARS-CoV-2 Infection Rescues B and T Cell Responses to Variants After First Vaccine Dose","volume":"372","author":"Reynolds","year":"2021","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine Over 6 Months","volume":"385","author":"Levin","year":"2021","journal-title":"New Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.10.060","article-title":"T Cell Immunity to SARS-CoV-2 Following Natural Infection and Vaccination","volume":"538","author":"DiPiazza","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2021.09.013","article-title":"Commercialized Kits to Assess T-Cell Responses Against SARS-CoV-2 S Peptides. A Pilot Study in Health Care Workers","author":"Martinez-gallo","year":"2021","journal-title":"Med Clin (Barc)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 Induced SARS-CoV-2 Neutralising Antibodies and T Cells in Humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00521-8","article-title":"Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals","volume":"10","author":"Jaganathan","year":"2021","journal-title":"Infect Dis Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2005.04.008","article-title":"The Duration of In Vitro Stimulation With Recall Antigens Determines the Subset Distribution of Interferon-Gamma-Producing Lymphoid Cells: A Kinetic Analysis Using the Interferon-Gamma Secretion Assay","volume":"301","author":"Desombere","year":"2005","journal-title":"J Immunol Methods"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.016","article-title":"Antibody Responses to the SARS-CoV-2 Vaccine in Individuals With Various Inborn Errors of Immunity","volume":"148","author":"Delmonte","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13188","article-title":"Qualitative Assessment of Anti-SARS-CoV-2 Spike Protein Immunogenicity (QUASI) After COVID-19 Vaccination in Older People Living With HIV","volume":"23","author":"Tuan","year":"2021","journal-title":"HIV Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","article-title":"Altered Cellular and Humoral Immune Responses Following SARS-CoV-2 mRNA Vaccination in Patients With Multiple Sclerosis","volume":"27","author":"Apostolides","year":"2021","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 Vaccination in Rituximab-Treated Patients: B Cells Promote Humoral Immune Responses in the Presence of T-Cell-Mediated Immunity","volume":"80","author":"Mrak","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.86.16_supplement.P2.158","article-title":"Does Rituximab Cause Depletion of T-Cells in Multiple Sclerosis and Neuromyelitis Optica","author":"Hardeman","year":"2016","journal-title":"Neurology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab179","article-title":"Haemodialysis Patients Show a Highly Diminished Antibody Response After COVID-19 mRNA Vaccination Compared With Healthy Controls","volume":"36","author":"Simon","year":"2021","journal-title":"Nephrol Dial Transpl"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.06.21256768","article-title":"Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis","volume":"32","author":"Anand","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03500321","article-title":"Humoral Immune Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis","volume":"16","author":"Grupper","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.06.025","article-title":"Humoral Response After Three Doses of BNT162b2 mRNA COVID 19 Vaccine in Patients on Hemodialysis","volume":"100","author":"Ducloux","year":"2021","journal-title":"Kidney Int"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.08.019","article-title":"Stage of Chronic Kidney Disease Predicts Seroconversion After Hepatitis B Immunization: Earlier is Better","volume":"42","author":"DaRoza","year":"2003","journal-title":"Am J Kidney Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.858399\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T05:24:43Z","timestamp":1726896283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.858399\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2022.858399"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.858399","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"article-number":"858399"}}